APLT

⚡ 1-Minute Take

Data sources: market data, fundamentals, news providers. Data may be delayed.

Key Statistics

📰 Latest News

Applied Therapeutics is pioneering treatments for unmet needs in cardiovascular disease, galactosemia, and diabetic complications, with Phase III trials underway for AT-001 and ongoing development of AT-007, positioning them for significant growth in the biopharmaceutical sector despite current financial challenges.

About APLT

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for cardiovascular diseases, galactosemia, and diabetic complications. Their pipeline includes AT-007 and AT-001, targeting rare metabolic disorders and diabetic complications, respectively.

Applied Therapeutics, Inc. Company Overview

Applied Therapeutics, Inc., founded in 2016 and headquartered in New York City, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for diseases with significant unmet medical needs. The company focuses on targeting cardiovascular disease, galactosemia, and diabetic complications. Their lead product candidate, AT-007, is being developed for the treatment of galactosemia, a rare genetic metabolic disorder. AT-007 has completed phase 1/2 clinical trials in healthy volunteers and adults and is currently in a pediatric clinical study. Additionally, AT-007 is being explored for treating sorbitol dehydrogenase deficiency and phosphomannomutase enzyme-CDG. The company's other key asset, AT-001, is in phase III clinical trials for the treatment of diabetic cardiomyopathy and diabetic peripheral neuropathy, two common and debilitating complications of diabetes. Applied Therapeutics also has preclinical programs, including AT-003 for diabetic retinopathy and AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Despite negative profit and gross margins, Applied Therapeutics is committed to advancing its pipeline and addressing critical healthcare challenges.

Investment Thesis

Investing in Applied Therapeutics presents a high-risk, high-reward opportunity. The company's focus on addressing unmet needs in cardiovascular disease, galactosemia, and diabetic complications offers substantial market potential. The ongoing Phase III trials for AT-001 in diabetic cardiomyopathy and diabetic peripheral neuropathy represent near-term catalysts. Positive trial results could lead to significant stock appreciation. The development of AT-007 for galactosemia, a rare disease, also provides a unique market opportunity. However, the company's negative profit margin of -1813.8% and gross margin of -2845.5% highlight the financial risks. Successful commercialization of their pipeline is crucial for long-term value creation. The company's high beta of 2.08 indicates significant volatility, making it suitable for investors with a high-risk tolerance.

Key Financial Highlights

• Market Cap of $0.01B reflects the company's current valuation and potential for growth.
• P/E Ratio of -0.83 indicates the company is not currently profitable.
• Profit Margin of -1813.8% highlights the significant expenses associated with clinical-stage drug development.
• Gross Margin of -2845.5% reflects the high cost of research and development relative to current revenue.
• Beta of 2.08 indicates the stock is more volatile than the market.

Industry Context

Applied Therapeutics operates within the biotechnology industry, a sector characterized by high innovation, significant regulatory hurdles, and substantial financial risk. The company focuses on developing treatments for cardiovascular diseases, galactosemia, and diabetic complications, all areas with considerable market demand. The biotechnology industry is experiencing growth driven by advancements in genomics, personalized medicine, and an aging global population. Competition is intense, with companies like CRBP and CRDF also pursuing novel therapies. Applied Therapeutics' success depends on its ability to navigate the complex regulatory landscape, secure funding, and demonstrate clinical efficacy.

Growth Opportunities

• AT-001 for Diabetic Cardiomyopathy: The market for diabetic cardiomyopathy treatments is substantial, driven by the increasing prevalence of diabetes globally. Positive Phase III trial results for AT-001 could position Applied Therapeutics as a leader in this space. The company aims to address a significant unmet need, potentially capturing a substantial share of the market, estimated to reach billions of dollars by 2030. The timeline for potential market entry is dependent on successful trial outcomes and regulatory approval.
• AT-001 for Diabetic Peripheral Neuropathy: Diabetic peripheral neuropathy affects millions worldwide. Successful development and commercialization of AT-001 for this indication could generate significant revenue. The market for DPN treatments is projected to grow, offering a substantial opportunity for Applied Therapeutics. The company's competitive advantage lies in its novel approach to addressing the underlying causes of DPN, rather than just managing symptoms. Market entry is contingent on trial results and regulatory approval.
• AT-007 for Galactosemia: Galactosemia is a rare genetic disorder with limited treatment options. AT-007 represents a potential breakthrough therapy. While the patient population is small, the unmet need is high, and regulatory agencies may offer incentives for developing orphan drugs. Applied Therapeutics could achieve significant market share in this niche market. The timeline for commercialization depends on the progress of ongoing pediatric clinical studies.
• AT-003 for Diabetic Retinopathy: Diabetic retinopathy is a leading cause of blindness. The development of AT-003, currently in preclinical stages, offers a long-term growth opportunity for Applied Therapeutics. The market for DR treatments is expanding, driven by the rising incidence of diabetes. Successful development of AT-003 could provide a competitive advantage in this growing market. The timeline for potential market entry is several years, given the preclinical stage of development.
• AT-104 for T Cell Acute Lymphoblastic Leukemia: AT-104, a PI3K inhibitor, targets orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. This represents a strategic expansion into oncology, offering diversification and potential for high returns in a niche market. Orphan drug designation could expedite the development and approval process. The timeline for commercialization is dependent on preclinical and clinical trial progress.

Competitive Advantages

• Proprietary drug candidates with patent protection.
• Clinical trial data demonstrating efficacy and safety.
• Orphan drug designation for certain indications, providing market exclusivity.
• Expertise in developing therapies for rare and underserved diseases.

Strengths

• Novel drug candidates targeting unmet medical needs.
• Phase III clinical trials underway for AT-001.
• Orphan drug designation potential for AT-007.
• Experienced management team with expertise in drug development.

Weaknesses

• Negative profit and gross margins.
• Limited financial resources.
• Reliance on successful clinical trial outcomes.
• High stock volatility.

Opportunities

• Positive clinical trial results leading to regulatory approvals.
• Partnerships with larger pharmaceutical companies.
• Expansion into new therapeutic areas.
• Orphan drug designation incentives.

Threats

• Clinical trial failures.
• Regulatory hurdles and delays.
• Competition from other biotechnology companies.
• Difficulty securing funding.

What APLT Does

• Develop novel therapies for cardiovascular diseases.
• Develop novel therapies for galactosemia.
• Develop novel therapies for diabetic complications.
• Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
• Pursue regulatory approvals for their drug candidates.
• Commercialize approved therapies to address unmet medical needs.
• Engage in preclinical research to discover new drug candidates.

Business Model

• Develop and patent novel pharmaceutical products.
• Out-license or partner with larger pharmaceutical companies for commercialization.
• Generate revenue through sales of approved therapies.
• Secure funding through venture capital, public offerings, and grants.

Key Customers

• Patients suffering from cardiovascular diseases.
• Patients suffering from galactosemia.
• Patients suffering from diabetic complications.
• Healthcare providers who prescribe and administer the company's therapies.
• Hospitals and clinics that utilize the company's products.

Competitors

• Corbus Pharmaceuticals Holdings, Inc. (CRBP): Focuses on developing and commercializing novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.
• Cardiff Oncology, Inc. (CRDF): Develops novel therapies targeting mechanisms of tumor resistance in cancer.
• Eltek Therapeutics, Inc. (ELTX): Unknown
• Forte Biosciences, Inc. (FBRX): Focuses on developing a live biotherapeutic for the treatment of inflammatory skin diseases.
• Milestone Pharmaceuticals Inc. (MIST): Develops and commercializes innovative pharmaceutical products for cardiovascular diseases.

Catalysts

• Upcoming: Phase III trial results for AT-001 in diabetic cardiomyopathy.
• Upcoming: Phase III trial results for AT-001 in diabetic peripheral neuropathy.
• Ongoing: Pediatric clinical study for AT-007 in galactosemia.
• Ongoing: Potential for orphan drug designation for AT-007.
• Ongoing: Preclinical development of AT-003 for diabetic retinopathy.

Risks

• Potential: Clinical trial failures for AT-001 and AT-007.
• Potential: Regulatory delays or non-approval of drug candidates.
• Ongoing: Competition from other biotechnology companies.
• Ongoing: Difficulty securing funding to support ongoing research and development.
• Ongoing: High stock volatility and potential for significant losses.

FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Related Stocks in Healthcare/Biotechnology

Browse More

Next Steps